Stayble Therapeutics publishes interim report for the first quarter 2023
Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached document and on the Company's website, www.staybletherapeutics.com/en/investors/financial-reports/. Below is a summary of the report.Summary Highlights during the first quarter (January – March 2023) · In February, the follow-up target in the Phase 2b study was reached, with 100 patients completing their six-month follow-up. All critical data for evaluating the study's primary efficacy parameter is therefore secured.